Could NIB shares beat the market in 2024?

Will next year be better for this private health insurer's shares?

| More on:
A man looking at his laptop and thinking.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

NIB Holdings Limited (ASX: NHF) shares have had an underwhelming time in 2023.

Since the start of the year, the private health insurer's shares have lost 4.5% of their value.

As a comparison, the ASX 200 index is up approximately 7% over the same period.

Will things be better for NIB shares in 2024?

There are a few factors that could have a major say on how NIB shares perform next year.

The first is the performance of the market as a whole. If interest rates are cut across the globe, it could give investor sentiment a major boost and drive shares higher.

Premium rate increases are another factor that could impact the company's share price. According to reports, the health insurance industry is seeking a 6% premium rate increase on average for next year.

While it is unclear if this will be approved, it is notably higher than what the market was expecting and compares to increases of 2.9% in 2023, 2.7% in 2022, and 2.74% in 2021. Goldman Sachs commented:

The 6% rate increase quoted in the AFR is higher than we expected noting claims cost inflation remains somewhat benign reflecting lower utilisation for mental health and rehab in particular.

What else?

Another factor to be aware of is the potential change to the NDIS.

NIB entered the NDIS market at the end of last year through the acquisition of plan manager, Maple. It raised $158 million to support its entry and has since made a number of other acquisitions, growing its presence in the market.

However, proposed changes to the NDIS could be a blow to its ambitions. A review is expected to be released in 2024.

Can its shares rise?

The good news is that Goldman Sachs has taken all the above into consideration and remains bullish on NIB shares.

It currently has a buy rating and an $8.40 price target on them, which implies a potential upside of 13.5% for investors over the next 12 months.

The broker also expects a fully franked 3.9% dividend yield for FY 2024, boosting the total potential return to approximately 17.5%.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »